|
시장보고서
상품코드
2152357
임상시험 시설 관리 기관 시장 규모, 점유율, 동향 분석 보고서 : 임상시험 서비스/구성요소별, 단계별, 치료 분야별, 지역별 및 부문별 예측(2026-2033년)Clinical Trial Site Management Organizations Market Size, Share & Trends Analysis Report By Clinical Trial Service/Component, By Phase, By Therapeutic Areas (Oncology, Cardiology, CNS), By Region, And Segment Forecasts, 2026 - 2033 |
||||||
세계 임상시험 시설 관리 기관(CSMO) 시장 규모는 2025년에 70억 달러로 추정되며, 2026년 74억 달러에서 2033년까지 119억 달러로 확대되어, 2026년부터 2033년까지 연평균 성장률(CAGR) 7.1%로 성장할 것으로 예측됩니다.
북미가 시장을 주도하고 있으며, 2025년에는 매출 점유율의 34.0%를 차지했습니다. 시장의 성장은 주로 만성 질환 및 감염병 유병률의 상승, 그리고 효율적인 임상시험 관리 솔루션에 대한 수요 증가를 배경으로, 제약사 및 생명공학 기업의 연구개발 투자 증가에 의해 주도되고 있습니다.
최근 전 세계적으로 임상시험 활동이 대폭 확대되면서 임상시험 실시 시설 관리 서비스에 대한 수요가 증가하고 있습니다. 임상 연구 인프라에 대한 투자 확대와 바이오의약품 연구개발 활동의 활성화가 임상시험 환경의 진화를 지속적으로 뒷받침하고 있습니다. 정부, 학술 기관, 민간 조직은 임상시험 접근성 향상, 환자 참여 촉진, 연구 역량 강화를 위한 노력에 투자하고 있습니다. 또한, 분산형 및 하이브리드형 임상시험의 도입 확대에 따라 환자 모집, 참여, 데이터 관리, 규제 절차 및 다기관 임상시험 조정을 지원하는 사이트 관리 조직에 대한 수요가 증가하고 있습니다.
기존에 임상 연구 시설은 극도로 세분화되어 있었으며, 주로 비상근 의사가 운영하는 진료소나 소규모 독립 기관으로 구성되어 있었습니다. 그러나 효율성과 확장성을 높이기 위해 공통된 소유 체제나 관리 네트워크 하에서 운영되는 시설이 증가하고 있어 통합이 가속화되고 있습니다. 임상 연구 업계에서는 주로 ‘독립된 연구 시설 또는 전문 연구 센터’와 ‘의사가 소속된 임상시험 시설’이라는 두 가지 시설 모델이 존재합니다.
자주 묻는 질문
목차
제1장 조사 방법 및 범위
제2장 요약
제3장 임상시험 시설 관리 기관 시장의 변수, 동향, 범위
- 시장 세분화 및 범위
- 시장 역학
- 보급률 및 성장 전망 분석
- COVID-19가 시장에 미치는 영향
- 주요 거래 및 전략적 제휴 분석
- 임상시험 시설 관리 기관(SMO) : 시장 분석 도구
제4장 임상시험 시설 관리 기관(SMO) 시장 : 임상시험 서비스/구성요소별 부문 분석
- 임상시험 시설 관리 기관(SMO) 시장 : 정의 및 범위
- 임상시험 시설 관리 기관(SMO) : 시장 점유율 분석(2025년 및 2033년)
- 임상시험 기관 관리
- 프로젝트 관리
- 현장 모니터링
- 규제
- 기타
제5장 임상시험 시설 관리 기관 시장의 단계별 분석
- 임상시험 시설 관리 기관(SMO) 시장 : 정의 및 범위
- 임상시험 시설 관리 기관(SMO) : 시장 점유율 분석, 2025년 및 2033년
- 제1상
- 제2상
- 제3상
- 제4상
제6장 임상시험 시설 관리 기관 시장의 치료 분야별 분석
- 임상시험 시설 관리 기관(SMO) 시장 : 정의 및 범위
- 임상시험 시설 관리 기관(SMO) : 시장 점유율 분석, 2025년 및 2033년
- 종양학
- 심혈관
- 중추신경계(CNS)
- 통증 관리
- 내분비
- 기타
제7장 임상시험 시설 관리 기관 시장의 지역별 분석
- 임상시험 시설 관리 기관(SMO) : 시장 점유율 분석
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
제8장 기업 개요
- 기업 개요
- Clinedge
- WCG
- ClinChoice
- Access Clinical Research
- FOMAT Medical Research INC.
- SGS
- KV Clinical
- SMO-Pharmina
- Xylem Clinical Research
- Aurum Clinical Research
- WCG
- Clinedge
The global clinical trial site management organizations market size was estimated at USD 7.0 billion in 2025 and is projected to grow from USD 7.4 billion in 2026 to USD 11.9 billion by 2033, growing at a CAGR of 7.1% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 34.0% in 2025. The market growth is primarily driven by increasing research and development investments by pharmaceutical and biotechnology companies, fueled by the rising prevalence of chronic and infectious diseases and the growing demand for efficient clinical trial management solutions.
In recent years, clinical trial activity has expanded significantly worldwide, driving increasing demand for clinical trial site management services. Growth in clinical research infrastructure investment and rising biopharmaceutical R&D activity continue to support the evolution of the clinical trials landscape. Governments, academic institutions, and private organizations are investing in initiatives to improve trial accessibility, patient engagement, and research capacity. In addition, the growing adoption of decentralized and hybrid clinical trials is increasing demand for site management organizations to support patient recruitment, engagement, data management, regulatory processes, and multi-site trial coordination.
Historically, clinical research sites have been highly fragmented, comprising primarily part-time physician practices and small independent organizations. However, consolidation is accelerating, with sites increasingly operating under common ownership or administrative networks to improve efficiency and scalability. The clinical research industry primarily comprises two site models, independent research sites or dedicated research centers and physician-affiliated clinical trial sites.
Global Clinical Trial Site Management Organizations Market Report Segmentation
This report forecasts revenue growth at the global, country, and regional levels, and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global clinical trial site management organizations market report based on clinical trial service/ component, phase, therapeutic areas, and region:
- Services/Component Outlook (Revenue, USD Million, 2021 - 2033)
Site Management
Project Management
Regulatory
Onsite Monitoring
Others
- Phase Outlook (Revenue, USD Million, 2021 - 2033)
Phase I
Phase II
Phase III
Phase IV
- Therapeutic Areas Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Cardiology
CNS
Pain Management
Endocrine
Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Italy
- Spain
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Table of Contents
Chapter 1 Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Estimates and Forecast Timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR's Internal Database
- 1.3.3. Secondary Sources
- 1.3.4. Primary Research
- 1.3.5. Details of Primary Research
- 1.4. Information or Data Analysis
- 1.4.1. Data Analysis Models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity Flow Analysis (model 1)
- 1.6.2. Volume Price Analysis (model 2)
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. List of Abbreviations
- 1.10 Objectives
- 1.10.1. Objective - 1
- 1.10.2. Objective - 2
- 1.10.3. Objective - 3
- 1.10.4. Objective - 4
Chapter 2 Executive Summary
- 2.1. Market Outlook
Chapter 3 Clinical Trial Site Management Organizations (SMOs) Market: Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1 Growth in the number of clinical Studies
- 3.2.1.2. Rising investment in R&D by the pharmaceutical companies.
- 3.2.1.3. Increasing rate of clinical trials outsourcing by pharmaceutical and biopharmaceutical companies.
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost of clinical studies
- 3.2.2.2. Presence of significant CROs offering site management services possesses the threat to steal its market share
- 3.2.1. Market Driver Analysis
- 3.3. Penetration & Growth Prospect Mapping
- 3.4. COVID-19 Impact on the Market
- 3.5. Major Deals and Strategic Alliances Analysis
- 3.6. Clinical Trial Site Management Organizations (SMO)s: Market Analysis Tools
- 3.6.1. Industry Analysis - Porter's
- 3.6.2. PESTEL Analysis
Chapter 4 Clinical Trial Site Management Organizations (SMOs) Market: Clinical Trial Services/ Components Segment Analysis
- 4.1 Clinical Trial Site Management Organizations (SMOs) Market: Definition & Scope
- 4.2 Clinical Trial Site Management Organizations (SMO): Market Share Analysis, 2025 & 2033
- 4.3 Site Management
- 4.3.1 Site Management Market, 2021 - 2033 (USD Million)
- 4.4 Project Management
- 4.4.1 Project Management market, 2021 - 2033 (USD Million)
- 4.5 Onsite Monitoring
- 4.5.1 Onsite Monitoring market, 2021 - 2033 (USD Million)
- 4.6 Regulatory
- 4.6.1 Regulatory Market, 2021 - 2033 (USD Million)
- 4.7. Others
- 4.7.1 Others market, 2021 - 2033 (USD Million)
Chapter 5 Clinical Trial Site Management Organizations (SMOs) Market: Phase Analysis
- 5.1 Clinical Trial Site Management Organizations (SMOs) Market: Definition & Scope
- 5.2 Clinical Trial Site Management Organizations (SMO) : Market Share Analysis, 2025 & 2033
- 5.3 Phase I
- 5.3.1 Phase I Market, 2021 - 2033 (USD Million)
- 5.4. Phase II
- 5.4.1 Phase II Market, 2021 - 2033 (USD Million)
- 5.5 Phase III
- 5.5.1. Phase III Market, 2021 - 2033 (USD Million)
- 5.6 Phase IV
- 5.6.1. Phase IV Market, 2021 - 2033 (USD Million)
Chapter 6 Clinical Trial Site Management Organizations (SMOs) Market: Therapeutic Area Analysis
- 6.1 Clinical Trial Site Management Organizations (SMOs) Market: Definition & Scope
- 6.2 Clinical Trial Site Management Organizations (SMO): Market Share Analysis, 2025 & 2033
- 6.3 Oncology
- 6.3.1 Oncology Market, 2021 - 2033 (USD Million)
- 6.4. Cardiology
- 6.4.1 Cardiology Market, 2021 - 2033 (USD Million)
- 6.5 CNS
- 6.5.1. CNS Market, 2021 - 2033 (USD Million)
- 6.6 Pain Management
- 6.6.1. Pain Management Market, 2021 - 2033 (USD Million)
- 6.7 Endocrine
- 6.7.1. Endocrine Market, 2021 - 2033 (USD Million)
- 6.8 Others
- 6.8.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7 Clinical Trial Site Management Organizations (SMOs) Market: Regional Analysis
- 7.1 Clinical Trial Site Management Organizations (SMO): Market Share Analysis
- 7.2 North America
- 7.2.1 North America Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.2.2 U.S.
- 7.2.2.1 U.S. Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.2.3 Canada
- 7.2.3.1 Canada Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.3 Europe
- 7.3.1 Europe Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.3.2 UK
- 7.3.2.1 UK Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.3.3 Germany
- 7.3.3.1 Germany Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.3.4 France
- 7.3.4.1 France Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.3.5 Italy
- 7.3.5.1 Italy Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.3.6 Spain
- 7.3.6.1 Spain Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033(USD Million)
- 7.3.7 Denmark
- 7.3.7.1 Denmark Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.3.8 Sweden
- 7.3.8.1 Sweden Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.3.9 Norway
- 7.3.9.1 Norway Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033(USD Million)
- 7.4 Asia Pacific
- 7.4.1 Asia Pacific Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.4.2 India
- 7.4.2.1 India Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.4.3 Japan
- 7.4.3.1 Japan Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.4.4 China
- 7.4.4.1 China Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.4.5 Australia
- 7.4.5.1 Australia Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.4.6 South Korea
- 7.4.6.1 South Korea Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.4.7 Thailand
- 7.4.7.1 Thailand Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.5 Latin America
- 7.5.1 Latin America Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.5.2 Brazil
- 7.5.2.1 Brazil Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.5.3 Mexico
- 7.5.3.1 Mexico Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.5.4 Argentina
- 7.5.4.1 Argentina Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.6 MEA
- 7.6.1 MEA Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.6.2 South Africa
- 7.6.2.1 South Africa Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.6.3 Saudi Arabia
- 7.6.3.1 Saudi Arabia Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.6.4 UAE
- 7.6.4.1 UAE Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
- 7.6.5 Kuwait
- 7.6.5.1 Kuwait Clinical Trial Site Management Organizations (SMOs) Market, 2021 - 2033 (USD Million)
Chapter 8 Company Profiles
- 8.1 Company Profiles
- 8.1.1 Clinedge
- 8.1.1.1 Company Overview
- 8.1.1.2 Financial Performance
- 8.1.1.3 Service Benchmarking
- 8.1.1.4 Strategic Initiative
- 8.1.2 WCG
- 8.1.2.1 Company Overview
- 8.1.2.2 Financial Performance
- 8.1.2.3 Service Benchmarking
- 8.1.2.4 Strategic Initiative
- 8.1.3 ClinChoice
- 8.1.3.1 Company Overview
- 8.1.3.2 Financial Performance
- 8.1.3.3 Service Benchmarking
- 8.1.3.4 Strategic Initiatives
- 8.1.4 Access Clinical Research
- 8.1.4.1 Company Overview
- 8.1.4.2 Financial Performance
- 8.1.4.3 Service Benchmarking
- 8.1.4.4 Strategic Initiatives
- 8.1.5 FOMAT Medical Research INC.
- 8.1.5.1 Company Overview
- 8.1.5.2 Financial Performance
- 8.1.5.3 Service Benchmarking
- 8.1.5.4 Strategic Initiatives
- 8.1.6 SGS
- 8.1.6.1 Company Overview
- 8.1.6.2 Financial Performance
- 8.1.6.3 Service Benchmarking
- 8.1.6.4 Strategic Initiatives
- 8.1.7 KV Clinical
- 8.1.7.1 Company Overview
- 8.1.7.2 Financial Performance
- 8.1.7.3 Service Benchmarking
- 8.1.7.4 Strategic Initiatives
- 8.1.8 SMO-Pharmina
- 8.1.8.1 Company Overview
- 8.1.8.2 Financial Performance
- 8.1.8.3 Service Benchmarking
- 8.1.8.4 Strategic Initiatives
- 8.1.9 Xylem Clinical Research
- 8.1.9.1 Company Overview
- 8.1.9.2 Financial Performance
- 8.1.9.3 Service Benchmarking
- 8.1.9.4 Strategic Initiatives
- 8.1.10 Aurum Clinical Research
- 8.1.10.1 Company Overview
- 8.1.10.2 Financial Performance
- 8.1.10.3 Service Benchmarking
- 8.1.10.4 Strategic Initiatives
- 8.1.1 Clinedge
